Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.00K | 59.00K | 192.00K | 441.00K | 441.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.00K | 59.00K | 192.00K | 441.00K | 441.00K |
| Cost of Revenue | 39.58M | 35.35M | 32.10M | 28.61M | 20.80M |
| Gross Profit | -39.52M | -35.29M | -31.91M | -28.17M | -20.36M |
| SG&A Expenses | 24.21M | 22.90M | 21.60M | 20.31M | 19.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.22M | 72.98M | 66.69M | 60.60M | 50.75M |
| Operating Income | -79.16M | -72.93M | -66.49M | -60.16M | -50.31M |
| Income Before Tax | -84.57M | -78.09M | -99.73M | -46.09M | 73.13M |
| Income Tax Expenses | 169.00K | 165.00K | 149.00K | 124.00K | 115.00K |
| Earnings from Continuing Operations | -84.74 | -78.26 | -99.88 | -46.22 | 73.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.74M | -78.26M | -99.88M | -46.22M | 73.01M |
| EBIT | -79.16M | -72.93M | -66.49M | -60.16M | -50.31M |
| EBITDA | -78.93M | -72.58M | -66.10M | -59.79M | -50.04M |
| EPS Basic | -5.83 | -6.11 | -8.79 | -5.62 | -2.77 |
| Normalized Basic EPS | -3.64 | -3.81 | -5.50 | -1.54 | 2.30 |
| EPS Diluted | -5.84 | -6.12 | -8.80 | -9.44 | -11.38 |
| Normalized Diluted EPS | -3.64 | -3.81 | -5.50 | -2.80 | 1.04 |
| Average Basic Shares Outstanding | 63.17M | 53.58M | 45.58M | 37.12M | 49.68M |
| Average Diluted Shares Outstanding | 63.17M | 53.58M | 45.58M | 42.36M | 54.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |